Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Veronika Bachanova, MD PhD , David H. McKenna, MD , Xianghua Luo, PhD , Todd E. DeFor, MS , Fiona He, MD , Murali Janakiram, MD MS , Erica D. Warlick, MD , Rose Wangen , Zuzan Cayci, MD , Bartosz Grzywacz, MD , Guy Brachya, PhD , Tony Peled, MSc , Jeffrey S. Miller, MD | ||||||||||||
Title | Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM) | ||||||||||||
|
|||||||||||||
URL | https://doi.org/10.1182/blood-2019-130476 | ||||||||||||
Abstract Text | Blood (2019) 134 (Supplement_1): 777 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GDA-201 | GDA-201 is composed of ex vivo activated donor natural killer cells, which may have persistent anti-tumor activity (Blood (2019) 134 (Supplement_1): 777). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|